EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study

Andrej Belančić iD, Marta Kučan Štiglić, Luka Prgomet, Ivan Pećin, Željko Reiner, Dinko Vitezić

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70122 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Andrej Belančić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia. Hauptthemen laut MEDLINE: Practice Patterns, Physicians', Drug Utilization, Hypolipidemic Agents, Dyslipidemias. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular diseases are the leading cause of mortality worldwide, with dyslipidemia as a major modifiable risk factor. This study aimed to assess 25‐year trends in lipid‐lowering agent consumption in Croatia from 2000 to 2023. We conducted a population‐based analysis using IMS and IQVIA databases, calculating drug utilization in defined daily doses per 1000 inhabitants per day (DDD/1000) and evaluating financial expenditures and prescribing patterns. Over the study period, total lipid‐lowering drug consumption increased more than 30‐fold, from 4.91 DDD/1000 in 2000 to 152.56 DDD/1000 in 2023. Statins, particularly atorvastatin and rosuvastatin, drove this trend, while the uptake of PCSK9 inhibitors and ezetimibe reflected an evolving therapeutic landscape. Financial expenditures peaked in 2010, declined until 2015, and rose again by 2023, with average drug prices per DDD decreasing significantly. The observed increase in lipid‐lowering therapy correlated with enhanced adherence to international guidelines and expanded patient access. However, administrative barriers and restrictive reimbursement policies continue to limit optimal utilization of newer agents. These findings underscore the importance of evidence‐based policy development to address clinical inertia and improve cardiovascular outcomes in Croatia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Practice Patterns, Physicians'Drug UtilizationHypolipidemic AgentsDyslipidemiasHumansCroatiaCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsDrug CostsFemale

Stichwörter der Autor:innen

cholesteroldyslipidemialipid‐lowering agentsstatins

Substanzen

Hypolipidemic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 Inhibitors

Autor:innen und Institutionen

  • Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia.
  • Department of Internal Medicine, Division of Metabolic Diseases, University Hospital Center Zagreb, Zagreb, Croatia.
  • Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia.

ORCID-Profile: Andrej Belančić

Zitieren

APA

Belančić, A., Štiglić, M. K., Prgomet, L., Pećin, I., Reiner, Ž., & Vitezić, D. (2025). Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70122

Vancouver

Belančić A, Štiglić MK, Prgomet L, Pećin I, Reiner Ž, Vitezić D. Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70122

BibTeX
@article{Belani2025,
  author = {Belančić, Andrej and Štiglić, Marta Kučan and Prgomet, Luka and Pećin, Ivan and Reiner, Željko and Vitezić, Dinko},
  title = {Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70122}
}
Kostenlos starten →